Conference reports

Efavirenz, tenofovir and emtricitabine associated with fewest adverse birth outcomes in Botswana

Adverse pregnancy outcomes and risk factors in the PROMISE trial

Women on lopinavir/ritonavir-based regimens at conception at higher risk of preterm delivery in UK study

No increase in adverse birth outcomes with maternal TDF/FTC in US study

Dolutegravir monotherapy studies halted due to integrase resistance: dual therapy studies continue

No evidence of accelerated brain ageing in HIV positive people on effective ART

Acute infection with wild-type HIV on PrEP with good drug levels

Fit for purpose: antiretroviral treatment optimisation (Feb 2017)

Seattle-lite: pre-conference workshops – watch online

International Congress of Drug Therapy in HIV infection (Glasgow 2016), 23-26 October 2016

1000-fold mark-up for drug prices in high-income countries blocks access to HIV, HCV and cancer drugs

Once-daily raltegravir formulation matches twice-daily results in age, gender, race and baseline viral load/CD4 subgroup analyses

Attachment inhibitor GSK-934/BMS-068: 96-week subgroup analysis in treatment-experienced patients

Once-weekly albuvirtide infusion: early results of T-20-like compound

Simplifying HIV treatment: dual therapy works but monotherapy with either boosted-PIs or dolutegravir does not

Dolutegravir-based ART in combination with rifampicin-based TB treatment is safe in a small cohort of co-infected patients

Further reports of CNS-related side effects with dolutegravir

Generic PrEP bought online for UK use is validated by drug testing service

Immunology and HIV persistence – implications for a cure

Selected webcasts from Glasgow 2016

2nd HIV Research for Prevention Conference (HIVR4P) 2016, 17-20 October 2016, Chicago

A burgeoning PrEP pipeline: dozens of new drugs, formulations and delivery options

Second case of drug resistant HIV infection in person adherent on PrEP

TDF/FTC can be used as PrEP by breastfeeding mothers without risk to the baby

Potential for EFdA as PrEP to prevent HIV transmission in women and their infants

Antibody therapy leads to sustained post-treatment SIV control in macaques

18th International Workshop on Comorbidities, 12-13 September, New York, USA

Fanconi-like lab abnormalities reported with daily PrEP: shows importance of routine kidney monitoring

Bone loss with PrEP in MSM aged 18-24

Neurological side effects with integrase inhibitors cause low rates of discontinuation in clinical practice

Atripla three days a week for two years: pilot switch study reports undetectable viral load with better bone, kidneys and sleep

Raltegravir increases waist circumference more than boosted PIs: greater with use of later ART

Exercise associated with significantly reduced risk of serious health problems and higher CD4 counts in large multicentre US study

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

Four day a week ART: sub-optimal drug levels but few virological failures

Large disparities in costs of antiretrovirals between low- and middle-income countries

High risk of virological failure and loss to follow up postpartum in South Africa

Birth weight and preterm delivery outcomes of vertically vs non-vertically infected HIV positive pregnant women

High death rates among HIV positive women postpartum accessing ARVs

Higher rates of eye complications in HIV positive people on ART

Short reports on selected Durban posters

Global HIV Clinical Forum: Integrase Inhibitors, 16 July 2016, Durban

Raltegravir-based third-line ART in children and adolescents

8th International Workshop on HIV Paediatrics, 15-16 July 2016. Durban, South Africa

Raltegravir in HIV-exposed neonates

Virological response without routine viral load monitoring in children: results from the ARROW trial

Tenofovir-containing ART reduces bone mineral density in breast feeding women: results from IMPAACT P1084s

21st International AIDS Conference (AIDS 2016), 18-22 July 2016, Durban, South Africa

AIDS 2016: online access to conference programme

ZERO: no linked HIV transmissions in PARTNER study after couples had sex 58,000 times without condoms

ZERO HIV transmissions in PARTNER study: most widely reported i-Base article

PrEP studies at AIDS 2016: includes first preclinical data with EFdA

Dual therapy with dolutegravir + 3TC keep viral load undetectable: 48 week results from PADDLE study

Once-daily raltegravir at last available: 48 week results from ONCEMRK study

Dual long-acting cabotegravir plus rilpivirine injections: 48-week results from LATTE-2

Dolutegravir is superior to boosted atazanavir in women in the ARIA study

PROMISE results support WHO recommendations for pregnant and breastfeeding women: more needs to be done to improve ART acceptability and adherence

Sub-Saharan African countries moving quickly to recommend “Treat All”

Efavirenz associated with suicide risk in analysis from START study

CD4:CD8 ratio is more sensitive marker of risk than CD4 counts in analysis from START study

Treatment in primary HIV infection is significantly more likely to normalise CD4:CD8 ratio

Publications launched at AIDS 2016

8th International Workshop on HIV paediatrics, 15-16 July 2016, Durban, South Africa.

No increased resistance with once daily dosing of abacavir and 3TC than twice daily dosing in the ARROW trial

TB 2016, 16-17 July 2016, Durban, South Africa

Post navigation